The Nomination Committee, in accordance with the principles adopted by the previous Annual General Meeting, consists of Andreas Ejlegård (Chairman), Joakim Söderström and Björn Dahlöf.

The Nomination Committee proposes the following Board: re-election of Board members Anders Svensson, Jeppe Øvlesen, Gunnar Olsson and Sten R. Sörensen and new election of board member Moi Brajanovic. Jeppe Øvlesen is proposed to be elected as Chairman of the Board (new election).

Statement from the Nomination Committee Chairman Andreas Ejlegård:

"The Nomination Committee has noted that the company is now entering a new phase with an increased focus on M&A and BD. Joakim Söderström has led the work of the Board in an exemplary manner during the last two terms of office. Although he has been available to the Nomination Committee for re-election, the Nomination Committee believes that a change in leadership on the Board is important to optimize the company's conditions in the upcoming phase.

Against this background, the Nomination Committee proposes a new composition of the Board to strengthen the opportunities to achieve the company's strategic goals. Jeppe Øvlesen is an internationally recognized authority in dealmaking and has the experience and competence required to successfully lead this work forward.

With Moi Brajanovic as a new member, the Board is provided with important expertise in business development and transactions - two key areas to drive the company to realize its strategic goals."

Moi Brajanovic (born 1987) holds a degree of master in economics with a focus on Business Administration from the School of Business, Economics and Law at the University of Gothenburg. Moi has extensive international experience from the finance sector, with a strong background in business development, due diligence and transactions (M&A). During his career, Moi has led complex risk and capital management assignments for international financial institutions. Moi is currently Managing Director at Advisense, a leading European company within governance, risk and compliance.

The Nomination Committee's other proposals will be presented in the notice of the Annual General Meeting that the Company plans to publish on Friday, May 9, 2025.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email:  tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:30 (CET) on May 7, 2025.

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.

Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1's safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.